Latest Financial Health News

MCS Security Services Limited reported a 63% revenue decline following the sale of its Security Business, yet improved its net loss and underlying EBITDA in FY25. The Traffic Business showed promising growth, while the company weighs capital management and potential divestments.

Maggie Beer Holdings reported a $24.3 million statutory loss for FY25 but showed promising sales growth and significant cost savings as it restructures for profitability.

Staude Capital Global Value Fund Limited has announced a fully franked ordinary dividend of AUD 0.033 per share for the half-year ending June 2025, accompanied by a dividend reinvestment plan offering a 2.5% discount.

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.

Harvey Norman Holdings Limited has announced a fully franked ordinary dividend of AUD 0.145 per share for the six months ending June 2025, signaling steady returns for shareholders.

Aerometrex Limited’s FY2025 results reveal a sharp decline in net tangible asset backing and a widening loss, signaling challenges ahead for the aerial imaging specialist.

K2 Asset Management posted a 17% revenue increase and returned to profitability in FY25, declaring a fully franked dividend and signalling plans for mergers and acquisitions to accelerate expansion.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

Enero Group posted a modest 2% EBITDA increase and improved margins in FY25 despite a 3% revenue dip, driven by operational efficiencies and strong second-half growth. The company declared a fully franked final dividend and sharpened its focus on core agencies after divesting OBMedia.

Novatti Group reports a record $51.8 million revenue for FY25 alongside a 65% improvement in underlying EBITDA, signaling a successful turnaround and a strategic pivot back to growth.

Visionflex Group reported a 49% rise in annual recurring revenue to $1.9 million despite a 33% drop in total revenue, driven by a pivot to subscription models and key government and corporate contracts.

Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.